Achievement of treatment goals and mortality in individuals with diabetes : the ELSA-Brasil study
dc.contributor.author | Chwal, Bruna Cristine | pt_BR |
dc.contributor.author | Reis, Rodrigo Citton Padilha dos | pt_BR |
dc.contributor.author | Schmidt, Maria Inês | pt_BR |
dc.contributor.author | Barreto, Sandhi Maria | pt_BR |
dc.contributor.author | Griep, Rosane Harter | pt_BR |
dc.contributor.author | Duncan, Bruce Bartholow | pt_BR |
dc.date.accessioned | 2024-02-09T05:06:23Z | pt_BR |
dc.date.issued | 2023 | pt_BR |
dc.identifier.issn | 2077-0383 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/271757 | pt_BR |
dc.description.abstract | Background: To prevent diabetes complications, the American Diabetes Association (ADA) has recommended the treatment of blood glucose, blood pressure, and LDL-cholesterol (LDL-c) to target levels. Our aim is to characterize the risk of death according to the achievement of these goals in subjects with diabetes participating in the ELSA-Brasil study. Methods: ELSA-Brasil is an occupational cohort study of middle-aged and elderly adults followed from a 2008–2010 baseline to 2019 by two additional clinic visits and annual telephone interviews. We ascertained known diabetes by self-reported diagnosis or anti-diabetic medication use. We used treatment targets based on the 2022 ADA guidelines. We ascertained deaths from any cause based on the annual surveillance confirmed by death certificates. Results: After 11 (1.8) years of follow-up, 261 subjects had died among 2423 with known diabetes. Within-target HbA1c was associated with the greatest protection (HR = 0.66; 95%CI 0.50–0.88) against all-cause mortality. Achieving both glycemic and blood pressure targets conferred substantial protection (HR = 0.54; 95%CI 0.37–0.78). Within-target LDL-c, however, was associated with increased mortality (HR = 1.44; 95%CI 1.11–1.88). Conclusions: Glucose and blood pressure control, especially when concomitant, reduced mortality. The increased mortality associated with achieving the LDL-c target merits further investigation. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Journal of clinical medicine. Basel. Vol. 12, n. 24 (2023), 7663, 17 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Diabetes mellitus | pt_BR |
dc.subject | Cardiometabolic risk factors | en |
dc.subject | Mortality | en |
dc.subject | Fatores de risco cardiometabólico | pt_BR |
dc.subject | Glycated hemoglobin A | en |
dc.subject | Mortalidade | pt_BR |
dc.subject | Hypertension | en |
dc.subject | Hemoglobinas glicadas | pt_BR |
dc.subject | Hypercholesterolemia | en |
dc.subject | Hipertensão | pt_BR |
dc.subject | Smoking | en |
dc.subject | Hipercolesterolemia | pt_BR |
dc.subject | Fumar | pt_BR |
dc.title | Achievement of treatment goals and mortality in individuals with diabetes : the ELSA-Brasil study | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001193458 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Files in this item
This item is licensed under a Creative Commons License
-
Journal Articles (39951)Health Sciences (10685)
-
Journal Articles (39951)Exact and Earth Sciences (6085)